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Inflammatory cytokines and biofilm 
production sustain Staphylococcus 
aureus outgrowth and persistence: 
a pivotal interplay in the 
pathogenesis of Atopic Dermatitis
E. G. Di Domenico  1, I. Cavallo1, V. Bordignon1, G. Prignano1, I. Sperduti2, A. Gurtner  3,  
E. Trento1, L. Toma4, F. Pimpinelli1, B. Capitanio5 & F. Ensoli1
Individuals with Atopic dermatitis (AD) are highly susceptible to Staphylococcus aureus colonization. 
However, the mechanisms driving this process as well as the impact of S. aureus in AD pathogenesis 
are still incompletely understood. In this study, we analysed the role of biofilm in sustaining S. aureus 
chronic persistence and its impact on AD severity. Further we explored whether key inflammatory 
cytokines overexpressed in AD might provide a selective advantage to S. aureus. Results show that 
the strength of biofilm production by S. aureus correlated with the severity of the skin lesion, being 
significantly higher (P < 0.01) in patients with a more severe form of the disease as compared to those 
individuals with mild AD. Additionally, interleukin (IL)-β and interferon γ (IFN-γ), but not interleukin 
(IL)-6, induced a concentration-dependent increase of S. aureus growth. This effect was not observed 
with coagulase-negative staphylococci isolated from the skin of AD patients. These findings indicate 
that inflammatory cytokines such as IL1-β and IFN-γ, can selectively promote S. aureus outgrowth, 
thus subverting the composition of the healthy skin microbiome. Moreover, biofilm production by 
S. aureus plays a relevant role in further supporting chronic colonization and disease severity, while 
providing an increased tolerance to antimicrobials.
Atopic dermatitis (AD) is a chronic skin disease characterized by impaired epidermal barrier function, cutaneous 
inflammation and a high degree of Staphylococcus aureus colonization in the skin lesions. AD affects approxi-
mately 15–30% of the children1,2 with 60% of cases occurring within a child’s first year and 85% before the age 
of 53. Mutations in the filament aggregating protein (filaggrin), which is encoded by the FLG gene, has been 
considered a major predisposing genetic element for AD4–7. Filaggrin is a natural moisturizing factor in the stra-
tum corneum of the skin and mutations in the FLG gene may impair the skin barrier function8–11. However, the 
majority of patients with AD do not harbour any mutation in the FLG gene and approximately 60% of mutation 
carriers do not present any clinical evidence of AD. This indicates that FLG mutations are neither necessary nor 
sufficient to cause AD, suggesting that other mechanisms affecting the skin barrier integrity may play a part in 
AD pathogenesis12–14.
The clinical hallmark of AD is the cutaneous inflammation, characterised by increased epidermal thick-
ness, enhanced expression of inflammatory cytokines and the presence of a dense infiltrate of activated CD4+T 
cells15,16. Based on the predominant expression of specific cytokines, the immune response in AD has been 
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described to develop in two distinct phases, early (acute) and late (chronic), respectively16,17. The interleukin 
(IL) 1 super family is the major epidermal proinflammatory cytokine complex involved in acute inflammation18. 
Increased level of IL-1, particularly IL-1β, correlates with signs of clinical exacerbation and progression of AD19,20. 
The initiation of the acute inflammatory response is also triggered by an increased Th2 activity, characterised by 
the expression of IL-4, IL-5, IL-13, and by a reduced production of interferon (IFN) γ. Conversely, the chronic 
phase of inflammation associates with an increase of the Th1 response, with an overproduction of IL-12 as well 
as of IL-5, IL-8 and IFN-γ, which represent the typical markers of chronic skin inflammation16. Notably, the 
overproduction of Th2 cytokines has been shown to alter the expression of different terminal differentiation 
proteins encoded by keratinocytes, including filaggrin, thus directly contributing to cutaneous barrier function 
impairment12,21,22. In addition, Th2 cytokines can downregulate the skin antimicrobial peptides (AMP) such as 
the human beta defensin (HBD)-2, HBD-3, and LL-37, which play major roles at contrasting colonization/infec-
tion of the skin by pathogenic bacteria23,24. Accordingly, microbiome analyses in AD lesions revealed a drastic 
reduction of the skin microbial diversity, with a low frequency of coagulase-negative staphylococci (CoNS), and 
an overabundance of S. aureus25,26. More than 80% of patients with AD appear to be permanently colonized with 
S. aureus in the eczematous skin lesions and disease severity has been directly correlated to the degree of S. aureus 
colonization22,25,27–30.
Antibiotic treatment usually reduces or apparently eliminates S aureus, however frequent recolonization 
occurs within few weeks with limited clinical improvement31,32. The difficulty in eradicating S. aureus coloniza-
tion with conventional antibiotic therapy may be evocative of the presence of biofilms. Indeed, S. aureus biofilms 
have been observed, as predominant species, in patients with AD lesions33–36.
The mechanisms governing S. aureus overabundance, its chronic persistence in the skin as well as bacterial 
factors capable of influencing AD clinical expression are as yet unclear.
In this study, we investigated whether biofilm production by S. aureus might play a part at sustaining S. aureus 
persistence and assessed its impact on AD severity. Besides, we evaluated whether biofilm production by S. aureus 
strains might impact antibiotic tolerance. Finally, we explored the possible relationship between the production of 
key inflammatory cytokines such as IL-1β, IL-6 and IFN-γ and the growth and adhesion capabilities of S. aureus 
strains isolated from patients with AD.
Results
Staphylococcus aureus colonization correlates with the severity of AD. From the 81 patients with 
AD, 42 were females (51.8%) and 39 (48.2%) males, aged between 3 months and 12 years. The overall prevalence 
of S. aureus on the lesional skin of AD patients was found to be 53.1% (44/81) (Table 1). In particular, S. aureus 
was isolated in 7 out of 25 (28.0%) patients classified with mild AD, in 17 out of 30 (56.6%) with moderate AD and 
20 out of 26 (76.9%) with the severe form of AD (Table 1). Comparative analysis showed that S. aureus coloniza-
tion was significantly lower in patients with mild AD as compared to individuals with moderate AD (P = 0.03) 
and to those with severe AD (P < 0.01). In contrast, the difference in the degree of S. aureus colonization in 
patients belonging to either the moderate or severe AD groups, was not significant (P = 0.07).
These data confirmed that an increased S. aureus colonization is associated with the severity of the skin lesion 
in AD.
High Biofilm producing isolates are associated with severe forms of AD. Previous reports sug-
gested that biofilm may represent a potential virulence determinant in AD33,35,37. To further address this issue, the 
presence of the intercellular adhesion genes (ica) A and D genes, which are specific biofilm-associated genes of the 
ica operon, was analyzed in all isolates. The results confirmed that all the strains were positive for both icaA and 
icaD genes suggesting that the S. aureus isolates have the potential to produce biofilm (Supplementary Table 1).
To confirm the results of the genetic analysis and to further evaluate the phenotypic expression and quantify 
the levels of biofilm production, all the S. aureus strains were tested by the clinical Biofilm Ring Test® (cBRT)38. 
The results showed that all isolates were able to produce biofilm, confirming that the simultaneous positivity to 
the icaA and icaD genes is always associated with the presence of biofilm-producing S. aureus35,39,40. In particular, 
43.0% of S. aureus strains were classified as high biofilm producers, 41.0% as moderate and 16.0% were identified 
as weak biofilm producers. By comparing the degree of severity of the skin lesions with the ability to produce 
biofilm emerged that 60.0% of patients with severe AD were colonized by high biofilm producers, 35.0% by 
moderate biofilm producers and only 5.0% by weak biofilm producers. In contrast, 57.1% of patients with a mild 
AD form were colonized by weak biofilm producers and only in 14.3% of them the colonization was sustained by 
high biofilm producers (Fig. 1). Statistical analysis showed that patients with severe AD had a significantly higher 
probability (P < 0.01) to be colonized by strong biofilm producer S. aureus strains as compared with patients with 
mild AD.
SCORAD N° of patients Positive Positive (%)
Mild 25 7 28.0
Moderate 30 17 56.6
Severe 26 20 76.9
Total 81 44 54.3
Table 1. Staphylococcus aureus prevalence in AD skin lesions.
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Confocal microscopy analysis provided results in good accordance with those gathered by the cBRT (Fig. 2). 
The strains identified as weak biofilm producer formed small cellular clumps on the surfaces of a polystyrene slide 
with a thin three-dimensional microcolony structures, the moderate biofilm producer developed much bigger 
clumps, whereas high biofilm producer exhibited a full coverage of the slide with the development of a thick and 
more structurally complex biofilm.
Antimicrobial susceptibility and identification of oxacillin-resistant S. aureus in patients with AD. 
The conventional antimicrobial susceptibility testing, performed in planktonic microbial growth, with all the 
S. aureus strains showed a high level of susceptibility to most antimicrobial agents (Fig. 3). However, 77.2% of the 
isolates were resistant to benzylpenicillin, 20.4% to erythromycin, 15.9% to clindamycin and 9.1% to gentamycin. 
Moreover, three strains were found resistant to oxacillin (6.8%). Further analysis of these three strains confirmed 
their resistance profiles showing the presence of the mecA gene, which confers resistance to methicillin, and the 
presence of penicillin binding protein (PBP2), as assessed by the latex agglutination test. Taken together these 
data indicate a very low prevalence of MRSA strains. Further, statistical analysis confirmed that the oxacillin 
resistance profile was not associated with a significant increase in the severity of AD (P = 0.36).
In vitro analysis of antibiotic susceptibility of biofilm-producing Staphylococcus aureus. It has 
been reported that the use of anti-Staphylococcus agents in the treatment of AD has a reduced efficacy with a high 
rate of re-colonization occurring after 4–8 weeks31. These data are apparently in contrast with the susceptibility 
profiles observed in this study and those previously reported32,41–43. Thus, we evaluated whether the ability to pro-
duce biofilm might sustain an increased antibiotic tolerance, which, in turn, may contribute to re-colonization. 
These studies were performed in 9 clinical isolates, equally divided in weak, moderate and strong biofilm pro-
ducers as described in Fig. 1. To ensure comparability of the data, the conventional Antimicrobial Susceptibility 
Testing (AST) and the Anti-Biofilm Test (ABT) were both performed by a broth dilution-based procedure, testing 
12 antibiotics. AST performed on the 9 isolates, gave similar resistance profiles with only one strain, within the 
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Figure 1. Biofilm production by Staphylococcus aureus isolates. Biofilm formation was assessed in the 44S. 
aureus strains isolated from patients with different degrees of AD. The severity of AD was classified as Mild, 
Moderate and Severe, respectively, according to the ‘scoring atopic dermatitis’ index (SCORAD). The values 
above the bars show the the exact number of biofilm-forming isolates. The level of biofilm production was 
measured by the clinical Biofilm Ring Test (cBRT) and the isolates classified as weak, moderate and high biofilm 
producers, respectively.
Figure 2. Confocal microscopy images of biofilms. Representative images of biofilms developed on polystyrene 
pegs following 24 h incubation at 37 °C. Staphylococcus aureus isolates are classified into three groups (weak, 
moderate and high) according to their biofilm-forming ability. Upper panels show the X-Y planes (top view), 
while the lower panels show the Z section (side view).
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group of the high biofilm producers, found resistant to clindamycin (Fig. 4A). Conversely, the antibiotic suscep-
tibility of S. aureus strains growing in mature biofilms, evaluated by ABT, gave resistance profiles which greatly 
differed (49.1% of the isolates) from those gathered by AST (Fig. 4B). By ABT testing, the most effective antibiot-
ics were found to be fusidic acid and oxacillin, with a minimal biofilm-eradication concentration (MBEC) value 
below breakpoints in 77.8% of isolates. Rifampicin was effective in 66.7% of isolates and daptomycin, gentamicin 
and teicoplanin in 55.6% of them. On the contrary, erythromycin, levofloxacin, tigecycline and trimethoprim/
sulfamethoxazole were the less effective antibiotics, showing a MBEC below breakpoints in only 33.3% of iso-
lates. The spectrum of antimicrobial efficacy was found to be further restricted when the analysis was focused on 
moderate/high biofilm producer S. aureus strains. With all these strains levofloxacin was totally ineffective while 
erythromycin, tigecycline, trimethoprim-sulfamethoxazole and vancomycin gave a MBEC below breakpoints 
in only 16.6% of the strains. Interestingly, the comparative assessment of susceptibility profiles gathered by AST 
and ABT considering separately the Weak, Moderate and High biofilm producer groups, revealed differences of 
11.1%, 55.6% and 77.8%, respectively. Statistical analysis confirmed significant differences of the antimicrobial 
susceptibility as assessed by AST and ABT in Weak (P = 0.01), Moderate (P < 0.001) and High (P < 0.001) biofilm 
producers, respectively. Further, ABT assessment showed also significant differences between Weak and both 
Moderate (P < 0.001) and High (P < 0.001) biofilm producers as well as between Moderate and High (P = 0.002) 
biofilm producers.
Cytokine-induced growth of S. aureus. The previous set of studies indicated that the presence of S. 
aureus correlates with disease progression and that microbial biofilm-production may allow for increased adhe-
sion and antibiotic tolerance, thus favoring an effective colonization and chronic persistence. Next, we sought to 
determine whether S. aureus colonization might take advantage from the inflammatory cytokine milieu which 
characterize the disease. To address this issue, we investigated whether IL-1β, IL-6 and IFN-γ, which are the 
major cytokines involved in the AD inflammatory response, were capable to support the growth of either plank-
tonic or biofilm growing S. aureus strains.
The initial inoculum for the S. aureus strains was 1.84 × 105 ± 5.13 × 104 CFU/ml. The bacterial counts after 
24 h of incubation in RPMI, including both planktonic and biofilm bacteria, was 9.05 × 108 ± 4.34 × 108, which 
gave a mean generation time of 118 minutes. The growth of S. aureus strains, measured as CFU/mL, was assessed 
in the presence of different concentrations (50, 20, 10 ng/mL) of IL-1β, IL-6 and IFN-γ, respectively. The results of 
these experiments, which are summarized in Fig. 5A,B, showed a concentrations dependent, significant growth 
increase of S. aureus isolates in the presence of IL-1β and IFN-γ but not with IL-6, after 24 hours of incubation. 
This effect was observed with both planktonic and biofilm cultures (Fig. 5A,B). Specifically, treatment with IL-1β 
at 50 ng/ml gave a significant (P = 0.002) difference of bacterial count in planktonic and biofilm growth condi-
tions, respectively, giving rise to a 23.6- and 7.9-fold increase. Conversely, no significant difference was observed 
with IL-1β at 10 and 20 ng/ml concentrations in both planktonic and biofilm cultures. In the presence of IFN-γ, 
S. aureus exhibited a concentration-dependent, significant increase of bacterial counts in planktonic cultures at 
10 (P = 0.04), 20 (P = 0.03) and 50 ng/mL (P = 0.001), respectively, with bacterial counts peaking at up to 14-folds 
(Fig. 5A). Similarly, IFN-γ exerted significant growth-promoting activities on biofilms at 20 (P = 0.03) and 50 ng/
mL (P = 0.006), respectively (Fig. 5B).
On the other hand, IL-6 did not show any significant growth increase of both planktonic and biofilm growing 
S. aureus strains after 24 hours of incubation, even at high cytokine concentrations (Fig. 5A,B).
Figure 3. Antimicrobial susceptibility testing for the 44 Staphylococcus aureus isolates. Percentage of 
susceptible (green) and resistant (red) strains to the indicated antimicrobials, as determined by broth micro-
dilution testing. Classification was performed according to the European Committee on Antimicrobial 
Susceptibility Testing clinical breakpoint tables (EUCAST Clinical Breakpoint Table v 7.1). TXP/SMX - 
Trimethoprim/Sulfamethoxazole
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The specificity of the growth-promoting activities of IL-1β and IFN-γ on S. aureus was further confirmed 
by neutralization experiments. The addition of anti-IL-1β and anti-IFN-γ neutralizing antibodies to the growth 
medium abolished the bacterial growth enhancement induced by either cytokine (Fig. 5A,B).
Figure 4. Comparison between the Antimicrobial susceptibility test (AST) and the Anti-Biofilm Test 
(ABT). (A) Overall percentage of susceptible (green) and resistant (red) Staphylococcus aureus strains to 
different antimicrobials as determined in the nine strains (N9). Comparison between AST and ABT in 
Weak (B), Moderate (C) and High (D) biofilm producing Staphylococcus aureus isolates. Classification was 
performed according to the European Committee on Antimicrobial Susceptibility Testing clinical breakpoint 
tables (EUCAST Clinical Breakpoint Table v 7.1). In brackets the number of strains analyzed. TXP/SMX - 
Trimethoprim/Sulfamethoxazole.
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Pro-inflammatory cytokines fail to stimulate the growth of coagulase-negative staphylococci. 
S. epidermidis and S. hominis are common skin commensals, representing the most abundant Coagulase negative 
staphylococcal species (CoNS) populating the skin microbiome44. Since CoNS and S. aureus share the same hab-
itat on the human skin, we evaluated whether the growth-promoting activities of inflammatory cytokines were 
selectively exerted on S. aureus or might also include other skin commensals such as S. epidermidis and S. homi-
nis. The initial inoculum for CoNS strains was 9.25 ± 3.77 × 104 CFU/ml. The bacterial counts after 24 h of incu-
bation in RPMI, was 9.40 × 108 ± 4.18 × 108 CFU/ml corresponding to a mean generation time of 127 minutes, 
which is remarkably similar to the mean generation time measured for S. aureus isolates. The growth of CoNS 
strains, in the presence of different concentrations of IL-1β, IL-6 and IFN-γ, showed that none of the cytokines 
tested had any effect on CoNS isolates in both planktonic and biofilm cultures (Fig. 5A,B). These data suggest that 
the ability to respond to cytokines may not represent a general property of staphylococci, but it is rather related 
to the acquisition of a specie-specific competence which confers a selective advantage to S. aureus strains with 
respect to other skin commensals.
Discussion
AD is the most common chronic inflammatory skin disease in the general population45. The pathogenesis of AD 
appears to be the result of a complex interplay between skin barrier defects and altered immune response22,46. 
The skin of individuals with AD is particularly vulnerable to colonization with S. aureus and an increasing body 
of evidence suggest that its presence correlates with skin inflammation and disease severity22,47. In agreement 
with previous reports we found that AD skin lesions appear particularly predisposed to S. aureus colonization. 
Specifically, of 81 patients with AD included in the study, 44 (54.3%) were colonized by S. aureus, with a different 
distribution according to the severity of the disease. S. aureus was present in 28.0%, 56.6% and 76.9% of patients 
with mild, moderate and severe forms of AD, respectively. Indeed, colonization with S. aureus was significantly 
higher in patients with moderate (P = 0.03) or severe (P < 0.01) AD than in individuals with mild disease forms. 
Prevalence analysis showed rates of S. aureus colonization of 75~90% in the lesional skin in AD, whereas in 
healthy individuals this bacterium is present only in 5~30% of cases, according to different studies33,48–50. The 
overall prevalence of S. aureus (53.1%) is lower than that previously reported, however, this apparent discrepancy 
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Figure 5. Growth response of Staphylococcus aureus isolates and coagulase-negative staphylococci (CoNS) 
to different concentrations of cytokines. Planktonic (panel A) and biofilm (panel B) bacteria were cultured 
overnight in RPMI medium alone (untreated) and in the presence of different concentrations of IL1-β, IL-6 
and IFN-γ. Data are expressed as fold increase (CFU/mL) between treated and untreated cells (dashed red 
line). The strains were tested in triplicate and experiments were repeated at least three times for each cytokine 
concentration. Mann-Whitney nonparametric test was used for statistical analysis. *Denotes P < 0.05.
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can be explained by the inclusion in our study of patients with moderate and mild forms of AD. Indeed, the prev-
alence of S. aureus in patients with severe AD peaks at 76.9%, which is in line with previously reported values.
We found that the majority of S. aureus strains isolated from AD lesions can produce several toxins and supe-
rantigens, which are thought to play an important role in the natural course of AD45,51–53. However, we did not 
find any direct relationship between the presence of a specific toxin gene and the severity of AD (Data not shown).
The mechanisms allowing S. aureus to preferentially colonize AD skin lesions are still unclear. The molec-
ular analysis aimed at assessing the presence of genes coding for biofilm components showed that all isolates 
harbored both icaA and icaD genes. This is in agreement with previous studies reporting that 92.5% of S. aureus 
strains isolated from AD patients were positive for both icaA and icaD genes35. To evaluate the interplay between 
S. aureus adhesion capabilities and the severity of AD, the phenotypic expression and quantitative production of 
biofilm was further examined by the cBRT38. We found that the ability to form biofilm by S. aureus isolates was 
significantly associated (P < 0.01) with the severity of the disease. Indeed, patients with more severe form of AD 
were invariably colonized by strong biofilm producers. This data suggest that biofilm represents a key factor for 
S. aureus persistent colonization in the eczematous skin of AD by enhancing adhesion and providing protection 
from the host immune response, competitor microbial species as well as antimicrobials35. This notion is indirectly 
reinforced by the results of confocal microscopy, which clearly shows the development of a thick, highly adhesive 
and structurally complex biofilm matrix, capable of exerting a remarkable barrier effect against multiple biologic 
and chemical insults.
The correlation between the overabundance of S. aureus and AD exacerbation, provides some support to the 
use of antibiotics for AD treatment. Although antibiotics can reduce or apparently eliminate S. aureus, recoloni-
zation frequently occurs within few weeks, with limited clinical efficacy31,32. Such a capability of chronic persis-
tence and relapse following antibiotic therapy is strongly suggestive of a biofilm-related colonization, which may 
explain the high tolerance of S. aureus to antimicrobial treatment31,32,41–43,54,55 as well as the conflicting evidence 
about the clinical benefit of the use of anti-staphylococcal agents31,32,56–59, even in those cases in which therapy was 
based on MIC results60. This does not appear to depend on the expression of multi drug resistance genes, since 
a very low prevalence of MRSA in AD has been previously reported41–43,61–63 and was found in the present study 
with only 6.8% of the isolates classified as MRSA.
The major problem in treating biofilm-related infections is due to the higher concentration of antibiotics 
required to kill bacteria, which can be hundred times higher than the MIC for the same microorganism as 
assessed by conventional AST performed in planktonic culture64–66. In our study, biofilm-growing cultures were 
found to be much more tolerant to antibiotics as compared to planktonic-growing cultures. The antibiotic sus-
ceptibility assessment by AST, revealed similar profiles among the different isolates (Fig. 4A). However, biofilm 
growing isolates showed increased levels of antibiotic tolerance as compared to their planktonic counterparts 
with significant differences among Weak (P = 0.01), Moderate (P < 0.001) and High (P < 0.001) biofilm produc-
ers, respectively (Fig. 4). In particular, biofilm production led to significant differences between Weak and both 
Moderate (P < 0.001) and High (P < 0.001) biofilm producers as well as between Moderate and High (P = 0.002) 
biofilm producers, respectively. Thus, tolerance of S. aureus isolates to antibiotics was directly related to the quan-
titative levels of biofilm production. Interestingly, we found that fusidic acid and oxacillin were the most effective 
molecules against biofilm-producing strains, with an MBEC below the threshold in approximately 80% of isolates. 
Further, our data showed that rifampin was active against biofilm-producing S. aureus with a MBEC below the 
threshold in 66.7% of isolates and this evidence is also consistent with previous studies reporting rifampin as an 
active compound against biofilm67.
Several studies have shown that local use of corticosteroids, even in the absence of antibiotics, reduces the 
colonization of S. aureus through an undefined process49,68–71.
Since corticosteroids mainly play an anti-inflammatory and immunosuppressive action, it is conceivable that 
cytokines involved in the inflammatory response may play a role in promoting S. aureus colonization. Thus, we 
evaluated the growth promoting activity of the prototypical cytokines involved in the acute (IL-1β, IL-6) and 
chronic (IFN-γ) phases of the disease on S. aureus strains isolated from AD patients with mild, moderate and 
severe forms of the disease, respectively. The cytokine concentrations we assessed have been previously tested and 
considered physiologically relevant in AD12,72–74. The results showed that IL-1β and IFN-γ but not IL-6 induce a 
significant growth enhancement on both planktonic- and biofilm-growing S. aureus strains in a concentrations 
dependent manner (Fig. 5). These results indicate that both early and late AD inflammatory cytokines are capable 
of supporting S. aureus planktonic and biofilm outgrowth during both the acute and chronic phases of the dis-
ease. These data further confirm earlier evidence of the growth promoting potential of IL-1β on S. aureus72,74,75. 
However, our data, which were gathered by testing field-isolated strains, show that IL-1β can stimulate the growth 
of both planktonic and biofilm cultures, while previous reports, dealing with reference laboratory strains, showed 
a growth enhancement for only the biofilm component. This is a relevant issue, since planktonic and biofilm 
microbial cells coexist in the same environment in vivo. The lack of growth-induction activity of inflammatory 
cytokines on other bacterial component of the skin microbiome suggests the existence of an adaptive response, 
specifically evolved by S. aureus and not present on CoNS, to take advantage of eukaryotic epigenetic signals. 
This selectivity provide support to S. aureus outgrowth at the expenses of other microbial commensals, further 
favoring S. aureus persistence. Indeed, these bacteria also produce potent and strain-specific AMPs which selec-
tively kill S. aureus. A low frequency of these species correlates with increased colonization by S. aureus, further 
reinforcing the notion that commensal skin bacteria have a protective role against pathogens25,26.
Since microbial biofilm is generally associated with disease chronicity, the response of S. aureus to IFN-γ may 
play a key role on AD disease severity. Indeed, previous reports showed that murine models defective for the Th1 
response were capable to clarify S. aureus from their nose more efficiently than their wild type counterpart and 
that the presence of IFN-γ played a detrimental role in murine defense against nasal colonization of slime pro-
ducing S. aureus ATCC 3555676. Regarding the lack of growth promoting activity by IL6, previous studies showed 
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that IL-6 enhanced the growth of fresh S. aureus isolates while this ability was lost in strains which underwent at 
least six plate passages72. Our isolates generally underwent at least 3/4 plate passages before the setting of cytokine 
cultures, thus we cannot exclude that this procedure caused the absence of a growth response to IL-6.
The molecular mechanism responsible for the growth response of S. aureus to cytokines remains to be 
defined, also considering that in eukaryotic cells the transduction of cytokine signals follows specific path-
ways which are putatively absent in bacteria. Nevertheless, cytokine-induced bacterial growth has been also 
shown in Acinetobacter spp. and Pseudomonas aeruginosa, while high levels of cytokines production cor-
relates with increased severity and mortality in critically ill patients harboring bacterial infections72,77,78. 
Interestingly, a methyl-accepting chemotaxis proteins (MCPs), including five chemoreceptors, has been 
recently described in Escherichia coli, having the potential to mediate growth enhancement in the presence 
of IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF) IL-15, and TNF-α79–82. The surface of 
Gram-negative bacteria has chemoreceptors responding to proinflammatory cytokines that have the potential 
to alter the microbial virulence properties82–84. In particular, TNF-α and IFN-γ induce E. coli translocation in 
the gut and IL-8 promote transmigration across human lung epithelium in pulmonary infections suggesting that 
inflammatory cytokines represent specific chemoattractants for bacterial translocation82–84. S. aureus might take 
advantage from a signalling process similar to that described for E. coli and involving biochemical pathways, other 
than those of the eukaryotic counterparts, capable of transducing the signal across the bacterial cell membrane 
and inducing gene modulation.
Although further research is needed to elucidate these mechanisms, our results suggest that specific cytokines 
produced during the acute and chronic AD phases can promote S. aureus outgrowth at the expenses of other 
microbial components of the skin microbiome and that microbial biofilm production can contribute at support-
ing bacterial adhesion, chronic persistence and increased tolerance to antimicrobials. It is tempting to speculate 
that the advantage provided by biofilm in promoting a persistent colonization, may also lead to a chronic release 
of toxins and superantigens, that, in turn, may either directly or indirectly contribute to the severity of AD. This 
might trigger a vicious circle that causes further barrier damages and a subsequent release of cytokines that addi-
tionally support S. aureus growth and chronic persistence (Fig. 6).
Thus, an interplay between host (inflammatory cytokines) and bacterial (biofilm production) factors may 
play pivotal roles in the pathogenesis of AD. This notion further supports the use of corticosteroids for the treat-
ment of AD, for their anti-inflammatory action and the ensuing expected impact on S. aureus colonization. The 
association of antimicrobials should be carefully evaluated on the basis of the assessment of their efficacy against 
bacterial biofilm.
Materials and Methods
Ethics Approval. The study was approved by the Central Ethics Committee I.R.C.C.S. Lazio, section of the 
Istituti Fisioterapici Ospitalieri, Rome (Prot. CE/1016/15—15 December 2015, trials registry N. 730/15). All 
the procedures and methods have been carried out in accordance with the guidelines laid down by the Ethics 
Committee and in accordance with local laws and regulations. Informed consent was obtained from all subjects.
Patients. Sample collection was performed on a total of 81 AD patients attending the Pediatric Outpatient 
Clinic at the San Gallicano Dermatology Institute of Rome, Italy from December 2015 to January 2017. There was 
S. aureus biofilm
Inflamed Skin
CoNS
Limited antimicrobials penetration 
CytokinesS. aureus Toxins 
Normal Skin
S. aureus CoNS
Normal skin microflora
AMP AMP
BA
Figure 6. Schematic illustration of the pathophysiological changes between normal (A) and inflamed skin in 
patient with atopic dermatitis (B). Arrows indicate increase (↑) and decrease (↓). The epithelium (https://smart.
servier.com/smart_image/epithelium-17/) is adapted from Servier Medical Art (http://smart.servier.com) 
under the Creative Commons License.
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no selection of patient’s gender, or severity of lesions. The study group comprised children aged between 3 months 
and 12 years, of both sexes (42 females and 39 males). All individuals were subjected to a complete clinical history 
followed by clinical examination. The clinical severity of AD was determined according to the ‘scoring atopic 
dermatitis’ index (SCORAD), as described by Hanifin and Rajka85. Accordingly, the clinical expression of disease 
was classified as mild, moderate, or severe according to SCORAD values ranging between 0 and 15, 15 and 40 
or >40, respectively33. Patients presenting with fungal infection or other skin diseases were excluded from the 
study, as well as those that received any steroid or antibiotic therapy in the last two months before study initiation.
Samples were collected by commercially available sterile swabs (COPAN swabs, Brescia, Italy), according to 
existing departmental guidelines. The samples were sent to the laboratory and processed within 30 minutes after 
collection for culture analysis.
Bacterial identification from skin samples. The swabs were plated onto blood agar, Mannitol Salt Agar 
(MSA) and S. aureus ID Agar (SAID) plates (bioMérieux, Bagno a Ripoli, Italy) for the initial identification of S. 
aureus and onto MacConkey agar and Sabouraud Agar (bioMérieux, Bagno a Ripoli, Italy) to verify the absence 
of Gram-negative bacteria and fungal infections. Inoculated plates were incubated aerobically for 24 hours at 
37 °C. The automated VITEK® 2 system (bioMérieux, Bagno a Ripoli, Italia) was used for the subsequent bac-
terial identification. Further microbial identification was performed by matrix assisted laser desorption/ioni-
sation – time of flight mass spectrometry (MALDI-TOF MS system – Bruker Daltonics, Bremen, Germany)86. 
Antimicrobial susceptibility testing (AST) was performed by the broth microdilution test (Thermo Scientific, 
Massachusetts, USA) for the definition of the Minimum Inhibitory Concentration (MIC) criteria, according to 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST Clinical Breakpoint Table v 7.1). The 
range of antibiotics tested is listed in the supplementary material section (Supplementary Table 2). Strains were 
classified as MRSA when presenting both oxacillin resistance (MIC ≥ 4 mg/ml) and positive agglutination test for 
Penicillin-Binding Protein (PBP2, Oxoid, Basingstoke, UK)87. S. aureus, S. epidermidis and S. hominis strains were 
frozen and stored in CRYOBANK (Copan, Brescia, Italia) at −80 °C.
Molecular characterization of Staphylococcus aureus virulence genes. PCR assay was used 
for the detection of S. aureus virulence genes among isolates. The NucliSENS® easyMAG automatic extractor 
(bioMèrieux, Florence, Italy) was used for total nucleic acid extraction from S. aureus isolates. Detection of the 
16 S rRNA gene was included as an internal positive control86. Reference strains from the American Type Culture 
Collection (ATCC): S. aureus ATCC 25923, S. aureus ATCC 6538, S. epidermidis ATCC 14990 and S. epidermidis 
ATCC 12228 were used as positive controls. The total bacterial DNA was amplified by PCR to assess the presence 
of the intracellular adhesion (ica) genes A and D35,39,40 and the gene for methicillin resistance mecA88,89. A com-
plete list of primers is provided in Supplementary Table 3.
Evaluation of Staphylococcus aureus biofilm production. Biofilm production by the S. aureus isolates 
was quantified by the clinical BioFilm Ring Test (cBRT) as previously described38,87. The test was performed using 
the reagents and equipment provided by the Biofilm Ring Test® kit (KITC004) and analysed by the BFC Elements 
3.0 software (Biofilm Control, Saint Beauzire, France)90. Specifically, two S. aureus reference strains (ATCC 25923 
and ATCC 6538) were included in each plate as standard reference and quality control. A well containing the 
BHI/TON mix without microbial cells was used as negative control in each experiment.
Each S. aureus strain was analysed in duplicate and experiments were repeated 3 times.
Biofilm Imaging. S. aureus colonies, grown overnight on blood agar plates, were used to inoculate 3 ml of 
0.45% saline solution (Air Life, Carefusion, CA, USA) to obtain a turbidity of 0.5 ± 0.1 McFarland (McF) cor-
responding approximately to 1 × 108 colony-forming units (CFU)/ml. Samples were diluted 1:1000 and resus-
pended in 3 ml of BHI containing sterile polystyrene slices of 1 cm2. Bacterial suspension was incubated at 37 °C 
for 22 hours to allow biofilm formation onto polystyrene slices. Subsequently, the medium was removed and 
the polystyrene slices were washed in 0.45% saline solution. The samples were stained using the LIVE/DEAD 
BacLight kit (Life Technologies, New York, NY, USA), according to supplier specifications. Images were collected 
by a Zeiss LSM 510 Meta confocal laser scanning microscope equipped with a 20X and 60X/1.23 NA oil immer-
sion objective (Carl Zeiss, Jena, Germany). Data were analyzed with the LSM 510 R. 3.2 META image analysis 
software (Carl Zeiss, Jena, Germany).
Anti-biofilm drug susceptibility testing. The anti-biofilm test (ABT) was performed by the protocol 
described in Chronopoulou et al. with some modifications91. Nine S. aureus strains, including three weak, three 
moderate and three strong biofilm producers, respectively, were collected from a blood agar plate and inoculated 
into 2 ml of 0.45% saline solution (Air Life, Carefusion, CA, USA) to obtain a turbidity of 0.5 ± 0.1 McF. Samples 
were diluted 1:100 in BHI and 100 μl of bacterial suspension, corresponding approximatively to 1 × 106 CFU/
ml, were seeded into a sterile 96-multiwell polystyrene plate (Corning Inc., Corning, NY, USA). The plate was 
incubated at 37 °C for 22 hours to allow biofilm formation. Subsequently, medium was removed and the wells 
were washed twice with 100 μl of sterile distilled water to remove non-adherent cells. The preformed bacterial 
biofilm was incubated for additional 22 hours in 100 μl of BHI in the presence of different antibiotics at prede-
fined concentrations (See supplementary material). After overnight treatment, antibiotics were removed, the plate 
washed twice with 200 μl of sterile distilled water and air-dried for 15 minutes at room temperature. Thereafter, 
the bottom of the wells was stained by 200 μl of a 0.1% violet crystal (CV) solution. After 20 minutes, the plate 
was washed two times with 300 μl of sterile distilled water to remove excess stain. The CV incorporated by the 
cells within the biofilm was dissolved in 200 μl of ethanol/acetone 80/20% and the optical density (OD) for each 
well was measured at 570 nm using the PhD™ lx System (Bio-Rad Laboratories, Hercules, CA, USA). Each plate 
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included 10 wells without bacteria as negative control and 3 wells plated with bacteria in the absence of antibi-
otics as positive controls. The cut-off value has been defined as three standard deviations above the mean OD570 
value of the negative controls. OD570 values above the threshold value identified bacterial growth and hence were 
used to identify the minimal biofilm-eradication concentration (MBEC), with reference to the EUCAST Clinical 
Breakpoint Table v 7.1 to identify the specific antimicrobial susceptibility.
Assessment of bacterial growth in the presence of cytokines. To determine the effects of 
cytokines on bacterial growth, a sterile 96-multiwell polystyrene plate was plated with 200 μl of an initial 
bacterial suspension of 1 × 105 CFU/ml in RPMI containing 2mM L-glutamine and 4 mM sodium pyruvate 
(EuroClone spa, Milan, Italy). Human cytokines interleukin (IL)−1β, IL-6 and IFN-γ (PeproTech, Rocky 
Hill, NJ, USA) were added to the culture medium at different concentrations (10 ng/ml, 20 ng/ml and 50 ng/
ml). Since cytokines were lyophilized in the presence of bovine serum albumin (BSA), a 0.1% solution of 
BSA (Sigma-Aldrich, St. Louis, MI, USA) was added in the wells containing the negative controls72. Bacterial 
cultures were incubated at 37 °C for 24 hours without shaking74. Subsequently, planktonic cells were collected 
with the supernatant and the wells were washed twice with 0.45% saline solution. To measure the number 
of the adherent cells remaining in the wells, bacteria were detached by scraping the bottom of the wells with 
a pipet tip and resuspended in 200 μL of sterile distilled water. Serial 10-fold dilutions of both planktonic 
and adherent bacterial cells were prepared and 5 μLwere spotted on blood agar plates (bioMérieux, Bagno 
a Ripoli, Italy). Plates were incubated at 37 °C for 24 hours and then counted to calculate the CFU/ml38. For 
the S. aureus experiments six strains were selected including two weak, two moderate and two strong biofilm 
producers, respectively. For CoNS, three S. epidermidis and three S. hominis isolates collected from the skin 
of AD patients were tested.
Blocking experiments were performed by adding the corresponding neutralizing monoclonal antibody in the 
culture medium, following manufacturer’s instruction (PeproTech, Rocky Hill, NJ, USA). Cytokines and neutral-
izing antibodies were incubated at 4 °C for one hour and then added to the growth culture medium. Subsequently, 
a bacterial suspension of 1 × 105 CFU/ml was added to each well and incubated at 37 °C for 24 hours. Planktonic 
and biofilm bacterial cells were counted as described above.
The bacterial growth rates and the mean generation time were calculated using the following equation:
= +log Nt log N g log 2 (1)10 10 0 10
where Nt is the number of cells after 24 h of incubation in RPMI and N0 is the number of cells at time zero.
Each strain was tested in triplicate and experiments were repeated at least three times for each cytokine 
concentration.
Statistics. Descriptive statistics were used to summarize pertinent study information. The association 
between SCORAD level and biofilm production was tested by chi-square test for linear trend. The Mann-Whitney 
nonparametric test was used to compare quantitative variables.
p-values of 0.05 or less were considered statistical significant. IBM SPSS v.21 statistics software (IBM, Chicago, 
IL, USA) was used for all statistical analyses.
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